Amazon’s $3.9 billion acquisition of primary care company One Medical was finalized last week without a regulatory challenge. Consumer protection groups say the deal shouldn’t have been allowed to close, citing a number of concerns — some of which are shared by the Federal Trade Commission, Health Care Dive reports. The agency, which reportedly had prepared a lawsuit to block the deal, could still sue to unwind the transaction farther down the road. Still, antitrust and M&A experts said that if regulators had found a reason to block the deal, they already would have. Read more.
Why Regulators Didn’t Challenge Amazon-One Medical Deal, Despite Data Concerns
